On Wednesday, Emergent BioSolutions Inc. EBS said it secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox, and mpox product portfolio.

周三，Emergent BioSolutions Inc.EBS表示，它在2024年和2025年获得了约4亿美元与痘苗、天花和mpox产品组合相关的订单。

What Happened: The order includes the previously disclosed U.S. government contract modification to procure ACAM2000 (Smallpox and Mpox (Vaccinia) Vaccine, Live), as well as CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) contract options exercised in 2023 and 2024.

发生了什么：订单包括之前披露的美国。S、 政府合同修改，以采购ACAM2000（天花和Mpox（痘苗）疫苗，活疫苗）以及CNJ-016[痘苗免疫球蛋白静脉注射（人）]（VIGIV）合同期权，于2023年和2024年行使。

To date, in 2024, nearly $210 million in customer orders have been delivered for ACAM2000 and VIGIV.

到目前为止，2024年，ACAM2000和VIGIV的客户订单已交付近2.1亿美元。

For the remainder of 2024 and into 2025, Emergent is confirmed to deliver more than $185 million in ACAM2000 and VIGIV orders.

2024年剩余时间到2025年，Emergent已确认将交付ACAM2000和VIGIV订单超过1.85亿美元。

“Emergent co1ntinues to be a trusted partner to supply medical countermeasures for biodefense and global health preparedness, and these incremental orders demonstrate our ongoing leadership to help address serious viral threats like smallpox and mpox,” said Joe Papa, president and CEO of Emergent.

Emergent总裁兼首席执行官乔·帕帕（JoePapa）表示：“Emergent Co1继续是一个值得信赖的合作伙伴，为生物防御和全球健康准备提供医疗对策，这些增量订单证明了我们在帮助应对天花和mpox等严重病毒威胁方面的持续领导力。”。

Why It Matters: In August, the FDA approved Emergent BioSolutions’ supplemental Biologics License Application (sBLA) to expand the indication for ACAM2000 to include preventing mpox disease in individuals at high risk for mpox infection.

重要原因：8月，FDA批准了Emergent BioSolutions的补充生物制剂许可证申请（sBLA），将ACAM2000的适应症扩大到包括预防mpox感染高危人群的mpox疾病。

Shortly after, Emergent announced that it submitted an Expression of Interest for the ACAM2000 vaccine to be assessed for Emergency Use Listing (EUL) with the World Health Organization (WHO).

不久之后，Emergent宣布，它向世界卫生组织（WHO）提交了一份对ACAM2000疫苗进行紧急使用清单（EUL）评估的意向书。

In furtherance of its commitment to support mpox response efforts, Emergent has donated 50,000 doses of ACAM2000 for potential deployment across impacted countries across the African continent.

为了进一步支持mpox应对工作，Emergent捐赠了50000剂ACAM2000，用于在非洲大陆受影响国家的潜在部署。

Last month, Emergent BioSolutions reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the consensus of $190 million.

上个月，Emergent BioSolutions报告称，2024年第二季度销售额为2.547亿美元，同比下降25%，超过了1.9亿美元的共识。

The company reported an adjusted EPS loss of $(2.32), more than double the $(1.05) reported a year ago, missing the consensus of $(0.94).

该公司报告调整后每股收益亏损（2.32美元），是一年前报告的（1.05美元）的两倍多，没有达到（0.94美元）的共识。

Emergent BioSolutions updated its 2024 Revenue guidance from $1 billion—$1.1 billion to $1.05 billion—$1.125 billion, versus the consensus of $1.03 billion.

Emergent BioSolutions将其2024年的收入指导从10亿美元-11亿美元更新为10.5亿美元-11.25亿美元，而共识为10.3亿美元。

Price Action: EBS stock is down 3.7% at $5.88 at last check Wednesday.

价格走势：周三最后一次检查时，EBS股价下跌3.7%，至5.88美元。

Read Next:

阅读下一页：

Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years.

。

Photo: UnsplashMarket News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

图片：Benzinga API为您带来的UnsplashMarket新闻和数据©2024 Benzinga.com。Benzinga不提供投资建议。保留所有权利。